- Category: About ICUS
About the ICUS Board…
Steven B. Feinstein, MD, FACC
Professor of Medicine
Rush University Medical Center
1750 W. Harrison Street, Room 1015 Jelke
Chicago, IL 60612-5020
Dr. Feinstein is an NIH-funded investigator, has authored more than 330 scientific publications, and is a frequent journal reviewer and lecturer throughout the United States and Europe. He is internationally recognized for his leadership in the CEUS field and developed the first two FDA-approved ultrasound contrast agents. His initial work focused on the use of CEUS for cardiac imaging, and has subsequently expanded to include CEUS assessment of vasa vasorem and carotid plaque. Dr. Feinstein also is developing therapeutic applications for CEUS that use ultrasound contrast agents to carry genes to the liver in order to increase the production of de novo HDL. His clinical practice focuses on preventive cardiology and early diagnosis of cardiac abnormalities.
In addition to serving as Co-president of ICUS, he serves as Program Director of the annual international “Bubble Conference” (Advances in Ultrasound), which he organized 26 years ago. He also has spoken to the FDA and other government agencies on the superior safety profile of CEUS and its clinical usefulness for detecting heart disease and monitoring therapy.
Stephanie Wilson, MD, FRCPC
Clinical Professor of Radiology and Gastroenterology - University of Calgary
Radiologist - Foothills Medical Centre
1403 29th Street, NW
Calgary AB Canada
First woman president of the Canadian Association of Radiologists.
Dr. Wilson is an internationally recognized expert in the use of CEUS for liver mass characterition and inflammatory bowel disease (IBD). Her experience in CEUS includes extensive clinical studies performed over the last 13 years, beginning with two single centre phase II trials for evaluation of the use of microbubble contrast agents in Radiology. These studies resulted in the approval of Definity (Lantheus Medical Imaging, Bellerica, MA) for liver mass characterization in Canada in 2002. Dr. Wilson shared two Canadian Institute of Health Research (CIHR) grants with Dr Peter Burns for the investigation of contrast agents for radiology practice in Canada.
Since the introduction of Definity for liver mass characterization in 2002, Dr. Wilson has become the most prominent and busy North American radiologist working routinely with ultrasound contrast agents. Dr. Wilson and her team perform several thousand examinations yearly, including approved uses for liver imaging and off-label uses involving characterization of masses in all other solid organs and the bowel. Further, we now recognize the value of CEUS to provide vascular information wherever it is felt that this information might be contributory to patient management or diagnosis. Dr. Wilson and her team have Letters of No Objection from Health Canada for our off-label research pursuits related to evaluation of the vasa vasorum in carotid artery plaque and also for monitoring disease activity with CEUS in patients with inflammatory bowel disease.
Petros Nihoyannopoulos, MD, FRCP, FESC, FACC, FAHA
Professor of Cardiology Imperial College London National Heart and Lung Institute
Hammersmith Hospital DuCane Road
London, UK W12 0NN
Past President of the British Society of Echocardiography (2001-2003)
Past President of the European Association of Echocardiography of the ESC (2006-2008)
Vice President, ICUS (2010-current)
Member of the Congress Program Committee of the ESC (2007-08) and Chair of the Imaging section.
Chair of Highlights Committee of the ESC (2009-10)
Founder of an annual Master’s degree on Medical Ultrasound at Imperial College London (Echocardiography, Vascular Ultrasound and Obstetrics & Gynecology)
Dr. Nihoyannopoulos is a national and international opinion leader in the field of cardiac ultrasound (echocardiography). He serves as Consultant Cardiologist responsible for managing patients with varied heart conditions admitted under his care. He also serves as head of the echocardiographaphy laboratories at Hammersmith Hospital and head of the teaching program for medical students, research fellows and junior doctors.
Dr. Nihoyannopoulos’ expertise in contrast echocardiography started in 1988, when he first started to use Albunex for improved endocardial border delineation. It was the first commercially available agent for this indication in Europe. Subsequently, in 1993, he led the first multicentre European study looking at the effects of the first saccharide-based transpulmonary contrast agent, Levovist, to study the effects this agent had in enhancing the Doppler signal in various clinical settings; this work led to a publication in JACC (1995; 25: 500-8). In 1994, Dr. Nihoyannopoulos started using EchoGen in various clinical studies, including renal, hepatic and cardiac enhancement of the Doppler signal and grey-scale sonograms, including stress; this work also led to several publications: Albrecht T, Cosgrove DO, et al. Acad Radiol (1996);3:S198-200, Cosgrove DO,et al. Ultrasound Quarterly (1998);14:66-75] and Calachanis M et al. Cardiovasc Imag (1999);11:123. Subsequently, in 1996, he instigated a multicentre study using a new ultrasound contrast agent, Infoson, during dobutamine stress echocardiography leading to the first poublication of this agent during stress [Ikonomidis I et al, Coronary Artery Disease (1998);66:229-33]. In 1998, he participated in the first multicentre European trial using a new agent, NC100100, for the assessment of myocardial perfusion in comparison with MIBI SPECT in a randomised multicentre study, looking at the safety of this agent. [Marwick TH et al. J Am Coll Cardiol (1998);32:1260-69] [Binder et al. Clin Cardiol (1999);22:273-282]. At the same time, he initiated a multicentre study comparing the use of myocardial contrast echocrdiography with NC100100 and Tc-99m SPECT for detecting myocardial perfusion abnormalities in patients with previous myocardial infarction [Jucquois I et al. Heart (2000);83:518-524].
In 1999, on behalf of the British Society of Echocardiography, Dr. Nihoyannopoulos’ work included production of a document on the clinical and economic outcomes in patient assessment using myocardial contrast echocardiography [Shaw LJ, Monaghan MJ, Nihoyannopoulos P. [Heart (1999);Suppl 3, 82:16-2]. By this time, his laboratory was using ultrasound contrast agents routinely for clinical purposes, both for established clinical indications but also off-label for myocardial perfusion during stress. In 2004, he participated in another collaborative study with King’s College London, on the first European contrast agent SonoVueTM [Brown AS, et al. Irish Journal Of Medical Science (2004)173 (1): 13-17]. In 2004, on behalf of the British Society of Echocardiography, he also paprticipated in the publication of procedure guidelines for the Clinical Application of Stress Echocardiography, which highlighted the use of contrast ultrasound [Heart (Suppl)(2004);90:vi23-vi30].
Dr. Nihoyannopoulos also has played a lead role in the publication of a number of European statements on the use of contrast echocardiography in clinical practice. Olszewski R et al. Eur J Echocardiogr (2007);8:S13-S23; Rakhit DJ et al. Eur J Echocardiogr (2007);8:S24-S29. In addition, in 2007, he led the European Committee for Laboratory Standards and published the European Association of Echocardiography recommendations [Nihoyannopoulos P et al. EAE laboratory standards and accreditation. Eur J Echocardiogr (2007);8:80-7.
In 2006, Dr. Nihoyannopoulos started a program at Imperial College to produce homemade Imperial microbbubles and conjugate them with antibodies to look at myocardial inflammation in mice. This program is now ongoing with extensive collaboration between chemists, physicists, basic scientists and clinicians.
David Cosgrove, MD, FRCR, FRCP
Imaging Sciences Department Clinical Sciences Centre
Imperial College London
Du Cane Road
London W12 0NN, UK
Michael Main, MD
Medical Director, Echocardiography Laboratory
Mid-America Heart Institute/Saint Luke’s Health System
4330 Wornall Road, #2000
Kansas City, MO 64111
Brian Fowlkes, PhD
Director, Basic Radiological Sciences Division
Department of Radiology
University of Michigan Health System
3226C Medical Sciences Building I
1301 Catherine Street
Ann Arbor, MI 48109-5667
Maria Cristina Chammas, MD, PhD
Director - Ultrasound Service
Hospital das Clinicas University of Sao Paolo
Av. Manoel dos Reis Araujo, 453
Sao Paolo - SP - Brazil
President-elect of FLAUS (Latin American Federation of ultrasound) for the biennium 2013-2015.
Director of the Department of Ultrasonography, Hospital das Clinicas, University of São Paulo - HC - FMUSP.
Coordinator of the São Paulo Ultrasound Society of Radiology and Diagnostic Imaging (SPR), since 2003.
Ex-Coordinator of the Ultrasound Committee of the Brazilian College of Radiology and Diagnostic Imaging (CBR). (2008-2010).
Member of the Ultrasound Committee of the Brazilian College of Radiology and Diagnostic Imaging. (2005-2008)
Past-Board Reviewer of the journal "Radiologia Brasileira".
Sociedade Paulista de Radiologia e Diagnóstico por Imagem (SPR).
Sociedade Brasileira de Ultrassonografia (SBUS)
Dr. Chammas is a radiologist and is active in internal medicine. Her primary expertise is in the use of CEUS to evaluate the liver, focal kidney diseases, transplants of kidney, liver and pancreas; breast and carotid arteries.
Kassa Darge, MD, PhD
Professor of Radiology - Perelman School of Medicine, University of Pennsylvania
Chief, Division of Body Imaging, Department of Radiology - The Children's Hospital of Philadelphia [CHOP]
34th Street & Civic Center Boulevard, Philadelphia, PA 19104-4399, USA
Dr. Darge is a nationally and internationally renowned pediatric radiologist and Chief of the Division of Body Imaging at the Department of Radiology of the Children’s Hospital of Philadelphia (CHOP), and Professor of Radiology at the Perelman School of Medicine at the University of Pennsylvania, where he also holds ‘The John Hope Endowed Chair’ for Radiology Faculty Development. Prior to joining CHOP, Dr. Darge was Professor and Head of the Department of Pediatric Radiology at the University of Wuerzburg, Germany.
As Chairman of the Pediatric Contrast-Enhanced Taskforce, Dr. Darge played an important role in the European Federation of Societies of Ultrasound in Medicine (EFSUMB) in contributing the pediatric part of the first CEUS guideline. He is a member of the Pediatric Uroradiology Subcommittees of both the European Society of Pediatric Radiology (ESPR) and the European Society of Urogenital Radiology (ESUR) and plays an active role in putting out the pediatric imaging guidelines regarding CEUS in uroradiology. He has had research collaborations with different ultrasound contrast agent manufacturers and was also involved in the design and introduction of pediatric specific CEUS software for a US company. Dr. Darge has made major contributions to, and was instrumental in, the introduction and advancement of the widespread use of contrast-enhanced voiding urosonography for the diagnosis of vesicoureteric reflux in children in Europe, South America and Asia.
As a pediatric radiologist, Dr. Darge has authored 34 scientific publications and has 73 published extracts on pediatric contrast enhanced ultrasound. He is a member of 26 professional societies and an editorial board member or reviewer of 23 scientific journals. He has received several awards including the "Schinz Medal" & "Honorary Membership" from the Swiss Radiological Society, the "Heidi Patriquin International Fellowship for Education Award" from the Society of Pediatric Radiology (SPR), "Contrast Agent Research Award" from the German Radiological Society and "The Schering Prize" from the EFSUMB.
Dr. Darge received his M.D. from Addis Ababa University, Ethiopia and his Ph.D. and Dr. Med from Heidelberg University, Germany. He is also an honorary professor at the Department of Radiology of the Faculty of Medicine at Addis Ababa University, Ethiopia, where he is responsible for the CHOP international pediatric radiology outreach program. Prior to his radiology career, Dr. Darge was a research fellow of the World Health Organization (WHO) at the Bernhard-Nocht Institute of Tropical Medicine in Hamburg, Germany.
Paul A. Grayburn. MD, FACC
Paul J. Thomas Professor of Medicine
Baylor University Medical Center
Associate Editor, American Journal of Cardiology
Editorial Boards, Circulation, JACC Cardiovascular Imaging, Heart
Dr. Grayburn has pioneered the use of ultrasound-targeted microbubble destruction for gene therapy. This work has resulted in cure of diabetes in rats, and work is now underway in a primate model. He has served on multiple committees for the American Society of Echocardiography, including the Task Force for Quantitation of Valvular Regurgitation. He is currently the PI for the MitraClip studies at Baylor Health Care System, and co-investigator for the Cardiothoracic Surgery Network Trials on mitral regurgitation. His background in both interventional cardiology and echocardiography, including intraoperative TEE during surgical mitral valve repair, give him a unique insight into percutaneous mitral valve therapies.
Dr. Grayburn has published more than 260 papers in the medical literature and has served as Associate Editor of the American Journal of Cardiology since 1997. He is on the editorial boards of Circulation, JACC: Cardiovascular Imaging, and Heart. He is currently serving on the Publications Committee for the EVEREST II Trial, and the Core Lab Committee and Steering Committee of the STICH Trial. He has held a NIH K24 grant for mentoring junior faculty and an R01 grant “Functional MR in Ischemic Cardiomyopathy” for 3D TEE evaluation of the mechanisms of functional MR in the STICH Trial. He also served as a Core Lab Director for Dr. Christopher Newgard’s program project grant “Novel Therapies for NIDDM.”
Dr. Paul Grayburn did his general cardiology fellowship under the tutelage of Dr. Anthony N. DeMaria at the University of Kentucky from 1984-1986, followed by a year of interventional cardiology training with Dr. David C. Booth. In 1988, he was recruited to the University of Texas Southwestern Medical Center by Dr. James T. Willerson, where he served on the faculty for 15 years. During that time, he was Director of the Echocardiography Laboratories at UT Southwestern, and Chief of Cardiology at the Dallas VA Medical Center, where he also practiced interventional cardiology. In 2002, Dr. Grayburn moved to Baylor University Medical Center to accept the Paul J. Thomas Chair in Cardiology Research and Education. Dr. Grayburn is a consultant for Abbott Vascular and receives grant support from the NIH, Abbott Vascular, Medtronic, GE Healthcare, and Guided Delivery Systems.
Wilson Mathias, Jr., MD, FACC
Cardiology, Director - Echocardiography InCor - Heart Institute
The University of Sao Paulo School of Medicine
Av. Dr. Eneas de Carvalho Aguiar, 44
Sao Paolo - SP - Brasil 05403-000
Professor Mark Monaghan, Ph.D., FRCP (Hon), FACC, FESC
Director, Non-Invasive Cardiology
Kings College Hospital Cardiology Department
Denmark Hill, London SE5 9RS, UK
Pintong Huang, MD, PhD
Prof. and Chief of Department of Ultrasound in Medicine
The Second Affiliated Hospital of Zhejiang University School of Medicine China.
Fabio Piscaglia, MD
Dept of Digestive Disease and Internal Medicine
General and University Hospital S.Orsola Malpighi
via Albertoni 15
40138 Bologna, Italy
Dr. Piscaglia heads the Center for Ultrasound in Internal Medicine at the University of Bologna. He is an internationally-recognized expert in the use of ultrasound and CEUS to detect and evaluate liver tumors and other abnormalities, and frequently publishes and lectures in the field. He also is president-elect of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB), served as general secretary of the 2000 congress of the World Federation of Ultrasound in Medicine and Biology (WFUMB), and is a peer reviewer for more than 15 scientific journals. Dr. Piscaglia also organized the Euroson School on CEUS in Liver, Biliary, Pancreatic and Gastrointestinal Disease and has been appointed director of the Clinical School in Liver Imaging of the European Society for the Study of the Liver for 2012. He also serves on the Editorial Board of Ultraschall / European Journal of Ultrasound.
Edward G. Grant MD, FACR
Professor and Chairman Department of Radiology
USC Keck School of Medicine
University Hospital, 1500 San Pablo St.
Los Angeles, CA
Dr Ed Grant represents the USA and Body Imaging. Ed has been an enthusiastic supporter of CEUS for many years and has performed several clinical studies both off label and, more recently, as part of the Bracco multi centre study for characterization of focal liver lesions performed in the USA.
Beverly Gorman, RDCS
ICUS Director - Sonography
IAC Director of Accreditation - Echocardiography
Ms. Gorman also is the Director of Accreditation for Echocardiography at the Intersocietal Accreditation Commission. She has extensive clinical expertise in both adult and pediatric echocardiography, having practiced in both private practice and large hospital settings. She began her career in 1981 as a medical assistant/cardiac sonographer, training in echo under the supervision of a registered sonographer and a cardiologist. In October 1988, she earned the designation of Registered Diagnostic Cardiac Sonographer (RDCS) in Adult Echocardiography by the ARDMS.
Barry Goldberg, MD, FACR
Director, Division of Ultrasound Jefferson Ultrasound Research and Education Institute (JUREI)
Thomas Jefferson University Hospital
132 South 10th Street
Philadelphia, PA 19101
Past president, World Federation of Ultrasound in Medicine and Biology
Past president, American Institute of Ultrasound in Medicine
Recipient of Gold Medal for Distinguished Service to Radiology - American Roentgen Ray Society
Dr. Goldberg has been at Thomas Jefferson University Hospital as Director, Division of Ultrasound and the Jefferson Ultrasound Research and Educational Institute (JUREI), since 1977. There, he established the ultrasound division that would grow to become one of the largest ultrasound facilities in the world.
He is a Past President of the American Institute of Ultrasound in Medicine and the World Federation of Ultrasound in Medicine and Biology. He is currently Co-President of the International Contrast Ultrasound Society (ICUS). His major research efforts have been devoted to the uses of ultrasound contrast agents. His first paper on this subject was published in 1973 and his research and publications on this subject are ongoing.
He has been named as a Fellow of the American College of Radiology, the American Institute of Ultrasound in Medicine, the Society of Radiologists in Ultrasound, the American Heart Association, the Council of Cardiovascular Radiology, and the American Institute for Medical and Biological Engineering. The Radiological Society of North America (RSNA) recognized Dr. Goldberg’s research accomplishments when they granted him the Outstanding Researcher Award, and his educational achievements when they granted him the Outstanding Educator award. The International Society of Radiology honored Dr. Goldberg for his contributions to the advancement of International Radiology by honoring him with its highest honor, the Antoine Beclere Medal. The American Roentgen Ray Society (ARRS) honored Dr. Goldberg with its highest honor, the Gold Medal for Distinguished Service to Radiology.
Dr. Goldberg has written 319 peer-reviewed papers and 96 chapters. He has written and/or edited 29 books and has received 148 grants from government, foundations and industry.
Lennard D. Greenbaum, MD, FACR, FAIUM, FSRU
Co-Director, The Hughes Center for Fetal Diagnostics
Winnie Palmer Hospital for Women & Babies, Orlando Health
83 West Miller Street
Orlando, FL 32806
Past-President, American Institute of Ultrasound in Medicine (AIUM)
Dr. Greenbaum’s major interest is Obstetrical Ultrasound. As a radiologist who performed most aspects of ultrasound for many years, he saw the potential of contrast enhanced ultrasound (CEUS) to improve ultrasound imaging and, therefore, patient care.
During his presidency of the AIUM (2005-2007) he led the organization’s effort to encourage the FDA to approve a non-cardiac indication for an ultrasound contrast agent (UCA). This culminated with the AIUM writing, at the request of the FDA, a guideline for the use of an UCA in the performance of a clinical trial. (Greenbaum, l; Burns, P; Copel J et al. American Institute of Ultrasound in Medicine Recommendations for Contrast-Enhanced Liver Ultrasound Imaging Clinical Trials. J Ultrasound Med. 2006 June; 26: 705-716.)